KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial.

Angela M Hong, Serigne N Lo, Gerald B Fogarty, Jonathan Stretch, Wei Wang, Pablo Fernandez-Penas, Richard C W Martin, Matthew Foote, H Peter Soyer, Jeremy Ruben, Victoria Mar, Lilian Rocha, Cyro Festa-Neto, Chris Wratten, Sam Hogarth, Helena Collgros, Amanda Glanz, Bruna Melhoranse Gouveia, Richard A Scolyer, Madeleine T King, Pascale Guitera

J Am Acad Dermatol 93(5) 1251-1260

PMID40683357
PMCID-
DOI10.1016/j.jaad.2025.07.028
发表日期2025-07-19
入排依据:This is an oncology, human, randomized Phase III trial with a drug-containing intervention (imiquimod) and original primary results. However, the primary efficacy endpoint is treatment failure at 24 months (a binary outcome), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. No Kaplan-Meier analysis or hazard ratio for a time-to-event outcome is reported. Therefore, it does not meet the specific eligibility criteria for time-to-event efficacy endpoints.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: For patients with lentigo maligna who are not suitable for surgery, radiotherapy, or topical imiquimod are alternative nonsurgical treatments. OBJECTIVE: This trial aimed to assess the efficacy, safety, and patient-reported health-related quality of life (HRQL). METHODS: A multiinstitutional, phase 3, randomized trial conducted between August 2015 and November 2021. Patients were randomized to radiotherapy or imiquimod. The primary end point was treatment failure at 24 months. Secondary end points included response at 6 months, development of invasive disease, toxicity and HRQL. RESULTS: Between August 2015 and November 2021, 126 patients were randomized. The response rate was 95% at 6 months in both groups. The treatment failure rates were low with 12 failures in the radiotherapy group and 6 in the imiquimod group at 24 months (Odd ratios, 2.35; 95% CI, 0.82-6.75; P = .11). Both were well-tolerated with mainly grade 1 and 2 acute skin toxicity with no significant differences between groups in skin symptoms or HRQL at long-term. Patients had significantly better emotional scores after treatment than at baseline in both groups. The trial is underpowered due to early cessation of recruitment. CONCLUSIONS: Both radiotherapy and imiquimod are efficient and well-tolerated treatments for lentigo maligna. Neither have negative impacts on HRQL at 24 months.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。